CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
Oya S, Ozawa H, Nakamura T, Mori A, Ochi S, Maehiro Y, Umeda M, Takaki Y, Fukuyama T, Yamasaki Y, Yamaguchi M, Aoyama K, Mouri F, Nagafuji K.
Oya S, et al. Among authors: aoyama k.
Int J Hematol. 2024 Jun 10. doi: 10.1007/s12185-024-03803-2. Online ahead of print.
Int J Hematol. 2024.
PMID: 38853211